The US Department of Health and Human Services (HHS) and the Department of Defense have modified their existing agreement with Novavax to secure additional doses of the Covid-19 vaccine, Adjuvanted (NVX-CoV2373).

Under the modified deal, Novavax will deliver up to 1.5 million additional doses of its Covid-19 vaccine.

The company stated that the deal would maintain the access of the US public to its vaccine.

It will also support smaller dose vials development, selection of strain according to the US Food and Drug Administration (FDA) recommendations, and transition to the commercial market.

The modified contract is backed by previously allocated federal funding from Biomedical Advanced Research and Development Authority, HHS, and the Administration for Strategic Preparedness and Response.

Novavax president and CEO John Jacobs said: “This agreement acknowledges the need to offer the American people a diverse Covid-19 vaccine portfolio and underscores the importance of Novavax’s partnership with the US Government to ensure continuous access to a protein-based option as part of public health measures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

“We look forward to continuing our collaboration with the US Government on the development of our Covid-19 vaccine to meet the requirements of the FDA and our commercial customers for the upcoming 2023/2024 vaccination campaign.”

The protein-based Covid-19 vaccine candidate is engineered from the genetic sequence of the SARS-CoV-2 strain and formulated with the company’s saponin-based Matrix-M adjuvant.

It was developed using the recombinant nanoparticle technology of Novavax.

The US FDA granted emergency use authorization to the vaccine for use in adults aged 18 and above and in adolescents aged 12 to 17 as a primary series.

The Adjuvanted vaccine was also indicated as a first booster dose for people aged 18 and above who cannot obtain an FDA-authorised mRNA bivalent Covid-19 booster vaccine, following the primary series of vaccination with an authorised or approved Covid-19 vaccine.